CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 19 enrolled
Drug / intervention
LY2940680drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT01919398
NCT01919398Phase 1Completed
CompareCT.gov

A Phase 1 Study of LY2940680 in Japanese Patients With Advanced Solid Tumors

Eli Lilly and Company·interventional·Posted Aug 9, 2013·Updated Sep 11, 2019

In Brief

A Phase 1 clinical trial evaluating LY2940680 for Neoplasm Metastasis. Completed, enrolled 19 participants across 2 sites.

Detailed Summary

The primary purpose of this study is to assess the safety and tolerability of LY2940680 up to the global recommended dose in Japanese participants with advanced solid cancers.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsNeoplasm Metastasis
CountriesJapan
Collaborators--

Timeline

Phase 1CompletedFinished
2014201520162017201820192020202120222023202420252026
First PostedAug 9, 2013
Enrollment StartAug 1, 2013
Primary CompletionMay 1, 2016
Study CompletionJun 28, 2017
TodayJul 2, 2026
Enrollment to primary: 2.8 yearsPosted 12.9 years ago

Interventions

LY2940680drug

Administered orally